Eskim

Quick links to important sections

Eskim

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eskim

Quick Facts

Property Description
Active ingredients Omega-3-acid Ethyl Esters, Omega-3 Triglycerides
Form Oral capsule (liquid-filled soft gelatin)
Pharmacological Class Antilipemic agent / Lipid-regulating agent
General Purpose Lowering critically high triglyceride levels
Origin Semi-synthetic derivative of long-chain PUFAs

What Kind of Medicine is Eskim?

Eskim is a prescription-only medication classified as an antilipemic agent, or a lipid-regulating agent, which is used to manage and significantly lower high levels of fat in the bloodstream. It is defined by its role as a therapeutic tool against dyslipidemia, specifically targeting severe hypertriglyceridemia. This class of medicine is utilized for reducing the risk of conditions associated with elevated blood fats. These agents are clinically used for patients requiring substantial lipid modification.


Composition and Source: Omega-3 Fatty Acids

The primary active ingredients in Eskim are the Omega-3-acid Ethyl Esters and Omega-3 Triglycerides, delivered in an oral capsule form. These components are semi-synthetic derivatives of long-chain polyunsaturated fatty acids (PUFAs), obtained from fish oil that has undergone extensive purification and concentration processes. Eskim’s specific formulation is designed as a combination product, providing a controlled and standardized blend of these two active forms of omega-3s. The specific concentration of the active omega-3 components, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), is intended to support therapeutic consistency.


How Eskim Helps Normalize Blood Lipids

Eskim's general purpose is to serve as an adjunct to diet for patients needing substantial reduction in circulating fats, particularly triglycerides. It functions by interacting with metabolic pathways in the liver, reducing the production of triglyceride-rich particles and subsequently lowering the amount of fats circulating in the blood. This mechanism involves decreasing the liver's production of fat-carrying particles. By decreasing hepatic synthesis of triglycerides and reducing Very Low-Density Lipoprotein (VLDL) levels, Eskim helps patients manage critically elevated blood lipid levels, providing a foundation for lipid management in adult patient populations with confirmed hypertriglyceridemia.

Regulatory References

  1. MedlinePlus: Triglycerides
  2. NIH: Mechanism of Omega-3 Fatty Acids

What side effects are possible with Eskim?

Eskim (esomeprazole) is a proton pump inhibitor generally well-tolerated, but like all medications, it can cause side effects. Most common side effects are typically mild and temporary, often resolving as the body adjusts to the treatment.

Common Side Effects

System Side Effects
Gastrointestinal Nausea, vomiting, diarrhea, constipation, flatulence, abdominal pain, dry mouth
Nervous System Headache, dizziness

Less Common and Serious Reactions

Though rare, some side effects may require immediate medical attention. These include signs of a serious allergic reaction, such as sudden swelling of the face, tongue, or throat, difficulty breathing, or severe skin rash (reddening, blistering, or peeling).

Other rare, but serious, effects associated with long-term use (typically over a year) may include:

  • Bone Fractures: Increased risk of fractures of the hip, wrist, or spine.
  • Nutritional Deficiencies: Low levels of magnesium (hypomagnesemia) or vitamin B12 deficiency.
  • Severe Diarrhea: Persistent, severe, or watery diarrhea which may be a sign of a gut infection.
  • Kidney Problems: Signs of kidney injury, such as a decrease in urine output or swelling.
  • Lupus Erythematosus: New or worsening of a specific autoimmune condition, often presenting as a rash on sun-exposed areas and joint pain.

Important Safety Information

Inform your healthcare provider if you have severe liver problems, a history of low magnesium levels, osteoporosis, or are taking certain HIV medications. Eskim may also cause blurred vision or drowsiness; caution is advised when driving or operating machinery until you know how the medication affects you. Consult your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for medicinal products containing Omega-3-acid Ethyl Esters/Triglycerides outlines the required emergency response in the event of overdosage.

Feature Official Regulatory Statement
Documented Overdose Presentations Overdosage experience is limited, but is documented as an exaggeration of known adverse reactions.
Physiological Systems Affected Primary manifestations include gastrointestinal disturbances (such as flatulence and nausea) and an increased risk of hemorrhagic events (bleeding).
Emergency-Response Management Treatment is officially defined as symptomatic and supportive treatment. No specific antidote is known.
When Immediate Medical Help is Required Seek immediate medical attention by contacting a Poison Control Center or emergency room upon known or suspected overdosage.

The regulatory profile confirms that the potential severity of an overdose is based on the exacerbation of these documented risks, particularly the risk of bleeding. The official guidance strictly mandates urgent medical evaluation for continuous clinical observation and supportive treatment of any presenting symptoms. The overdose profile applies uniformly, as regulatory documents do not explicitly detail specific differences in management for various patient populations.

Therapeutic Uses of Eskim

What Eskim Treats: Main Uses and Benefits

Eskim is a prescription medication relevant for conditions characterized by systemic imbalance stemming from high lipid levels. Its use is applied across domains where additional symptomatic support is needed, primarily within the field of cardiovascular and metabolic management. The medicine is indicated for use in certain adult populations.

Treatment of Profound Hypertriglyceridemia

Eskim is primarily relevant for managing profound hypertriglyceridemia, a condition where triglycerides are critically elevated, typically 500 mg/dL. The primary use is for patients who require a significant reduction in circulating blood fats to manage this systemic burden. This supports a substantial reduction in the overall level of lipids in the blood, which is commonly used to help with supporting metabolic stability.

Supportive Management of Acute Risk

The medication is applied in addressing the health risks associated with critically elevated blood fats. This supports a substantial reduction in the overall lipid load, which may assist with easing the impact of acute complications. The medicine is considered relevant when supportive symptom management is appropriate, as it supports a reduction in the overall lipid load, with the goal of reducing the occurrence of related health events.


Quick Fact: Relief for Systemic Imbalance

Focus Benefit Provided
Primary Condition Severe hypertriglyceridemia (TG 500 mg/dL as relevant)
Therapeutic Role Supports management of systemic imbalance
Key Benefit Contributes to easing the overall symptom load

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Eskim — Official Regulatory Information

Category Official Regulatory Statement
Eligibility Scope
Populations for whom use is allowed (as stated in label) Adult patients with severe hypertriglyceridemia (triglycerides 500 mg/dL) as an adjunct to diet.
Populations for whom use is not recommended (if applicable) Pediatric population (children and adolescents) because safety and effectiveness have not been established.
Populations for whom use is contraindicated Patients with known hypersensitivity (e.g., anaphylactic reaction) to the active ingredients (omega-3-acid ethyl esters) or any component of the formulation.
Age-related eligibility rules
Age-related eligibility rules Pediatric: Use is not established and not recommended. Geriatric: Appropriate studies have not demonstrated geriatric-specific problems that limit usefulness, though data in patients over 70 is limited.
Condition-specific eligibility rules
Condition-specific eligibility rules Hepatic impairment: Requires periodic monitoring of liver enzyme levels (ALT and AST). Underlying conditions: Use is conditional on attempting to control medical issues like diabetes mellitus and hypothyroidism.
Pregnancy and lactation eligibility status
Pregnancy and lactation eligibility status Pregnancy: Use is conditional; only if the potential benefit justifies the potential risk to the fetus (FDA Category C). Lactation: Caution should be exercised as the effect on the infant is unknown, or should not be used (as per different regulatory documents).
Eligibility-related restrictions
Eligibility-related restrictions Use with caution in patients with known hypersensitivity to fish and/or shellfish. Possible association with more frequent recurrences of symptomatic atrial fibrillation or flutter.

Eligibility Classifications (High-Level)

Category Classification Details (Strictly Regulatory Wording)
Eligibility severity classification Contraindicated (Hypersensitivity); Not Recommended (Pediatric Use); Use with Caution (Fish Allergy, Hepatic Impairment).
Regulatory basis FDA Prescribing Information / EMA Summary of Product Characteristics (SmPC).

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use Eskim by establishing a narrow eligible patient population—adults with severe hypertriglyceridemia—and setting absolute exclusions, primarily for patients with known hypersensitivity. Furthermore, they mandate conditional use or caution for patients with specific pre-existing conditions (e.g., hepatic impairment, heart rhythm issues) and reproductive statuses (pregnancy, lactation), reflecting data limitations or documented risks found in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines documented interactions based on governmental regulatory information. "Eskim" (Esomeprazole) may interact with certain other medicines through two main mechanisms: by significantly raising the stomach's pH or by affecting specific liver enzymes involved in drug breakdown, primarily CYP2C19.

Category or Specific Medicine Interaction Constraint or Requirement
Certain Antiretrovirals (e.g., Nelfinavir, Atazanavir) Do not combine with Nelfinavir. Concomitant use with Atazanavir is generally not recommended due to significantly reduced exposure to the antiretroviral agent.
Clopidogrel (Antiplatelet Agent) Avoid concomitant use. The use of Eskim may reduce Clopidogrel's conversion to its active form, potentially affecting its intended function.
Warfarin (Anticoagulant) Close monitoring of INR and prothrombin time is required upon starting or stopping Eskim, as the drug may elevate the plasma levels of Warfarin.
pH-Dependent Drugs (e.g., Ketoconazole, Iron Salts, Erlotinib, Digoxin) The reduction of stomach acid may decrease the absorption of agents that require an acidic environment. Monitoring for Digoxin toxicity may be necessary.
Methotrexate Co-administration, particularly with high-dose Methotrexate, may increase the exposure of Methotrexate. Temporary withdrawal of Eskim may be required during treatment.

The official interaction profile is structured to mandate restrictions or requirements for monitoring due to potential changes in the concentration of the co-administered drug. This includes outright avoidance for critical combinations like Nelfinavir, and dose adjustments or close clinical observation for agents like Warfarin and Tacrolimus.

Mechanism of Action

Regulating Hepatic Fat Production at the Molecular Level

Eskim exerts its primary effect by modulating gene transcription within the liver. The active omega-3 components act as agonists of the nuclear receptor PPAR-alpha while suppressing the transcription factor SREBP-1c, which contributes to reducing the production of enzymes required for fat synthesis. This molecular modulation increases the rate of fatty acid breakdown (beta-oxidation) relative to assembly into triglycerides.


Inhibiting Triglyceride Assembly and VLDL Secretion

This mechanism is applied at the level of fat assembly by inhibiting key enzymes like DGAT, which catalyze the final steps of triglyceride formation. By modulating the final assembly step, the mechanism reduces the amount of triglycerides packaged into Very Low-Density Lipoprotein (VLDL) particles, which lowers the quantity of these particles released from the liver into the bloodstream.


Dual Action: Reduced Synthesis and Enhanced Clearance

The mechanism involves a coordinated action: the suppression of new triglyceride production is complemented by the upregulation of enzymes like Lipoprotein Lipase (LPL), which increases the rate of breakdown and removal of existing circulating triglycerides. This dual modulation of both supply and clearance contributes to the overall physiological modulation of fat concentration throughout the vascular system.

Dosage and Administration Information

How to Use Eskim

Eskim (Omega-3-acid Ethyl Esters) is a prescription medicine intended for oral administration and is utilized as an adjunct to diet for the long-term management of high blood lipids. The medication is characterized by specific administration parameters.


Standard Dosing and Frequency

The standard and maximum recommended daily dose for adults is 4 grams (4,000 mg). This total daily amount is typically initiated immediately, without a lower starting dose or titration schedule. The full 4-gram dose may be administered in one of two ways: either once daily (taking four 1-gram capsules simultaneously) or as a divided dose of two 2-gram administrations per day.

Administration Conditions

Eskim capsules are taken with meals to support optimal absorption of the active ingredients. The soft gelatin capsules are to be swallowed whole; the capsules are not intended to be broken open, crushed, dissolved, or chewed prior to ingestion. In instances of a missed dose, the general protocol involves taking it as soon as remembered, unless it is close to the time of the next scheduled dose, in which case the missed dose is omitted.


Use in Specific Populations

While no specific dose adjustment is mandated for older adults or patients with renal impairment, there is a clinical focus on periodic monitoring of liver function in individuals with hepatic impairment. The safety and effectiveness of this medicine have not been established for use in pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eskim

Research Evidence for Severe Hypertriglyceridemia

The primary evidence base for Eskim's use, where studies evaluated severe hypertriglyceridemia (critically high levels of triglycerides in the blood), comes from short-term, randomized, controlled trials (RCTs). In these studies, adult patients with confirmed high triglyceride levels, often defined as 500 mg/dL, received either the medicine or an inactive placebo as an addition to a controlled diet. Research examined these groups over defined time intervals to see how blood lipid biomarkers changed.

The studies monitored the percentage change in fasting triglyceride levels as a main research outcome. Research examined these changes and documented the patterns observed in the studied populations. Findings describe the data gathered related to this primary blood fat marker.

Study Design and Outcomes Examined

The studies that included Eskim's active ingredients were typically 12-week trials that required patients to adhere to a lipid-lowering diet throughout the observation period. Beyond triglycerides, studies monitored changes in other fat-carrying particles, including Very Low-Density Lipoprotein Cholesterol (VLDL-C) and Low-Density Lipoprotein Cholesterol (LDL-C).

However, data show patterns related to LDL-C levels, where an increase was observed in some studies in certain patients receiving the medicine. This finding contributes to the broader evidence landscape; periodic monitoring of this marker was observed to be relevant in the research setting.

Long-Term Evidence and Durability of Effect

The core evidence regarding Eskim's active ingredients is based on the short-term adjustment of blood fat biomarkers. Because of the limited follow-up durations, long-term effects are not fully established regarding the durability of the observed responses over many years.

Furthermore, the initial, shorter-term studies primarily focused on measuring changes in blood biomarkers rather than examining clinical events. Therefore, there is limited information for long-term outcomes such as whether the research findings provide definitive data on reduced rates of major cardiovascular events like heart attack or stroke in this specific population. It is also not fully established whether the observed changes affect the risk of serious acute conditions like pancreatitis, which is sometimes associated with very high triglyceride levels.

Evidence in Specific Patient Populations

Data for certain groups remain insufficient. For example, evidence is limited regarding the inclusion of this medicine in studies of pediatric patients or in adults with certain coexisting conditions not fully represented in the primary trials. Therefore, research provides context but not individual predictions for people outside the main study groups.

Key Limitations and Uncertainties in the Research

The core research describes a link between the medicine and changes in lipid biomarkers over a short-term period, but the data does not establish long-term clinical outcomes (like major cardiovascular events or overall survival). Findings describe group patterns related to certain cholesterol markers, where some patients saw increases in LDL-C. The evidence contributes to understanding symptom patterns, but the results apply only to the specific populations and circumstances studied.

Key Studies & References

  1. The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: A systematic review and meta-analysis of randomized controlled trials
  2. Omega-3-acid ethyl esters for severe hypertriglyceridemia: A review of clinical data

Frequently Asked Questions (FAQ)

Common questions about Eskim (FAQ)

Q: Is Eskim the same type of medicine as [similar drug name]?

A: Eskim is officially classified as an antilipemic agent, meaning it’s a medicine used to lower fats in the bloodstream. Its action is primarily focused on reducing the production of triglycerides and Very Low-Density Lipoprotein (VLDL) in the liver. This action describes its role within the larger category of lipid-regulating agents.

Q: How long does it typically take for Eskim to start working?

A: Official studies designed to examine Eskim's effect on blood fat levels were generally short-term, most often lasting 12 weeks. These clinical trials monitored and documented changes in blood lipid markers over that period. The effect of the medicine is typically monitored through blood tests ordered by a healthcare professional.

Q: What are the most common side effects people report online for Eskim?

A: The official product information lists the most commonly documented side effects from clinical trials. These typically include gastrointestinal issues such as eructation (burping), upset stomach (dyspepsia), and a change in how things tastes (taste perversion). Consultation with a healthcare professional is appropriate if concerning side effects are experienced.

Q: Does Eskim affect sleep or cause insomnia?

A: Yes, regulatory information indicates that insomnia (difficulty sleeping) is a documented, though uncommon, adverse reaction associated with the use of this medicine. Consultation with a healthcare professional is appropriate if sleep changes are experienced.

Q: Are there any foods or drinks that should be avoided while taking Eskim?

A: Regulatory labeling instructs that Eskim capsules must be taken with meals to ensure the active ingredients are absorbed correctly. Additionally, official guidance advises that discussion regarding the use of the medicine with alcohol and tobacco with a healthcare professional is advised.

Q: Is Eskim a maintenance drug that needs to be taken long-term?

A: Yes, Eskim is officially indicated for the long-term management of high blood lipids (triglycerides). It is prescribed as a long-term addition to a controlled diet for specific adult patients.

Q: Does Eskim interact with caffeine or alcohol?

A: Official patient guidance emphasizes that discussion regarding the use of Eskim with alcohol with a healthcare professional is advised. Specific interaction data for common substances like caffeine is not typically detailed in the official regulatory labeling.

Q: Is it normal to feel tired when first starting Eskim?

A: Official data documents 'unusual tiredness or weakness' as a potential side effect. However, the exact frequency of this occurrence is not known based on the regulatory adverse event reporting.

Q: What is the experience of people who have been on Eskim for over a year?

A: The foundational clinical research for Eskim's approval was based on short-term trials, often around 12 weeks. Because of this, the long-term effects on the durability of the response and on major clinical outcomes like heart attack or stroke are not fully established by the core evidence.

Q: Are there generic versions of Eskim available?

A: Yes, the primary active components in Eskim, which are Omega-3-acid Ethyl Esters, are widely available in various generic formulations that have been approved by regulatory bodies like the FDA.

Q: Why does my doctor need to check my blood while I'm on Eskim?

A: Official labeling advises periodic monitoring of blood levels for several reasons documented in the labeling. These reasons include checking the function of the liver, assessing coagulation status if taking certain interacting medicines like Warfarin, and monitoring the medicine’s effect on various lipid markers.

Q: Is Eskim a controlled substance?

A: No, Eskim (Omega-3-acid Ethyl Esters) is classified as a prescription-only medication and an antilipemic agent. It is not categorized as a controlled substance under regulatory scheduling.

Q: Can Eskim affect my mood or emotional state?

A: Official adverse reaction reports document uncommon psychiatric effects in some patients. These documented reactions include symptoms such as insomnia, tics, and tantrums.

Q: Can Eskim interact with birth control pills?

A: Official drug interaction information for the active ingredients of Eskim does not specifically list an interaction with common oral contraceptive agents (birth control pills).

Q: Are there lifestyle changes that help Eskim work better?

A: Yes, Eskim is designed to be used as an adjunct to diet. Official guidance recommends that patients should follow an appropriate lipid-lowering diet and that any existing medical conditions contributing to high lipids, such as diabetes mellitus or hypothyroidism, should be kept controlled.

Q: What does 'contraindication' mean regarding Eskim?

A: A contraindication is a condition that makes the use of a medicine unsafe and therefore strictly forbidden. Eskim is officially contraindicated for any patient with a known hypersensitivity (a severe allergic reaction) to its active ingredients or any component of the formulation.

Q: Why do some people say Eskim didn't work for them?

A: Eskim is approved for use only in a specific patient population (adults with very high triglycerides). The results observed in clinical trials apply to the studied groups, but official documents caution that research findings do not provide individual predictions for every single patient.

Q: Can Eskim be taken with pain relievers like ibuprofen or Tylenol?

A: Eskim may prolong bleeding time, which is a general safety consideration documented in the labeling. Because of this potential effect, periodic monitoring is required when Eskim is taken alongside any other medication that affects coagulation, such as anti-platelet agents (a category that includes some pain relievers).

Q: What are the signs that Eskim is working correctly?

A: The purpose of Eskim is to modulate the body’s metabolism to reduce triglyceride levels. The primary indication that the medicine is working correctly is the observed change in blood lipid markers during follow-up tests, which are monitored by a healthcare professional.

Q: Does Eskim expire quickly after opening?

A: Yes, Eskim has a regulated shelf life after the container is first opened. For instance, some regulatory documents specify that the shelf life for capsules stored in the original HDPE container is 120 days after the first opening.

Q: Are the side effects of Eskim permanent?

A: Most common side effects are generally described in the labeling as mild and temporary, often resolving as the body adjusts. However, certain serious effects, such as a risk of bone fractures and kidney problems, have been associated with long-term use (typically over one year).

Q: What is the full list of ingredients in Eskim?

A: The active ingredients are Omega-3-acid Ethyl Esters and Omega-3 Triglycerides. Inactive ingredients, or excipients, used in the capsule typically include components such as gelatin, glycerin, purified water, alpha-tocopherol (as an antioxidant), and soybean oil.

Q: Are Eskim tablets available in different strengths?

A: According to the official prescribing information, Eskim is supplied as a single dosage form: a 1-gram transparent soft-gelatin capsule.

Q: Can people with heart disease use Eskim?

A: Official warnings and precautions advise caution in certain patients with heart rhythm issues. The labeling notes there is a possible association with a more frequent recurrence of symptomatic atrial fibrillation or flutter in patients who have a history of these conditions.

How should Eskim be stored and disposed of?

According to regulatory labeling, Eskim capsules must be stored under specific conditions to ensure product integrity and safety.

Official Storage and Handling Requirements

Requirement Details
Temperature Controlled Room Temperature (20 C to 25 C), with permitted excursions to 30 C.
Protection Protect from moisture and excessive heat; do not freeze.
Container Keep in the original container and ensure it is tightly closed.
Child Safety Store out of the reach and sight of children.

Disposal

Disposal instructions require that any unused or expired Eskim must be discarded in accordance with local requirements for pharmaceutical waste. The medicine should not be flushed down the toilet or placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Eskim found in:

A-Z Index: